India's Supreme Court rejection of Novartis's patent application for Gleevec—a leukemia drug that costs tens of thousands of dollars annually in Western markets—represented the most significant assertion of a developing country's right to limit pharmaceutical patent rights in the name of public health since the Doha Declaration of 2001, and sent an immediate signal to other nations seeking policy space for generic drug production.

The court upheld a decision by India's patent office that Gleevec's active compound, imatinib, was not sufficiently innovative compared to earlier compounds to warrant patent protection under India's pharmaceutical patent standards. Section 3(d) of India's Patents Act requires that modifications to existing compounds demonstrate significantly enhanced efficacy—a provision inserted specifically to prevent the practice known as "evergreening," in which pharmaceutical companies make minor modifications to existing drugs to extend patent life without meaningful therapeutic improvement.

Novartis argued that the ruling undermined innovation incentives globally. The company had invested in developing Gleevec and argued that the patent system's reward structure was essential to justify that investment. Without the ability to recoup development costs through protected pricing, future drug development would suffer.

Health advocates and generic drug manufacturers argued the opposite: that essential medicines must be accessible to populations in developing countries who cannot pay Western prices, and that a legal framework that permits such pricing while blocking generics condemns patients to preventable deaths.

The global implications were immediate. India supplies generic drugs to much of the developing world; the ruling protected the legal framework that makes that supply possible.

The tension between innovation incentives and access to medicine has no clean resolution. The Gleevec ruling chose access.